Sign in
4

Changes in Ownership

Adaptive Biotechnologies Corp Filed Acc 0001062993-25-002744

CEO and Chairman sold 470,368 shares at an average $8.47 ($3,985,754)

  • CEO and Chairman acquired 470,368 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

ROBINS CHAD M · CEO and Chairman

Table I: Non-derivative

6 lines
Date Transaction Shares Price Value Owned after D/I
2025-02-13 Exercise or conversion : show line 1 in the form 10b5-1 +100,287 $6.32 $633,814 2,676,988 D
2025-02-13 Sale : show line 2 in the form 10b5-1 −100,287 $8.44 $846,422 2,576,701 D
2025-02-14 Exercise or conversion : show line 3 in the form 10b5-1 +158,921 $6.32 $1,004,381 2,735,622 D
2025-02-14 Sale : show line 4 in the form 10b5-1 −158,921 $8.46 $1,344,472 2,576,701 D
2025-02-18 Exercise or conversion : show line 5 in the form 10b5-1 +211,160 $6.32 $1,334,531 2,787,861 D
2025-02-18 Sale : show line 6 in the form 10b5-1 −211,160 $8.50 $1,794,860 2,576,701 D
Open-market sales · 470,368 sh · avg $8.47 · $3,985,754

Table II: Derivative

3 lines
Date Transaction Shares Owned after D/I
2025-02-13 Exercise or conversion : show line 7 in the form 10b5-1 Stock Option (right to buy) −100,287 655,268 D
2025-02-14 Exercise or conversion : show line 8 in the form 10b5-1 Stock Option (right to buy) −158,921 496,347 D
2025-02-18 Exercise or conversion : show line 9 in the form 10b5-1 Stock Option (right to buy) −211,160 285,187 D
Loading xslF345X05/form4.xml…